valproic acid has been researched along with Diabetic Nephropathies in 5 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Diabetic Nephropathies: KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Valproic acid (VPA) is a first-line drug used for the treatment of epilepsy and migraine as well as established as a HDAC inhibitor." | 1.42 | Sodium valproate ameliorates diabetes-induced fibrosis and renal damage by the inhibition of histone deacetylases in diabetic rat. ( Jena, G; Khan, S; Tikoo, K, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Coughlan, MT | 3 |
| Ziemann, M | 3 |
| Laskowski, A | 3 |
| Woodruff, TM | 3 |
| Tan, SM | 3 |
| Khan, S | 2 |
| Jena, G | 2 |
| Tikoo, K | 2 |
| Kumar, V | 1 |
| Sun, XY | 1 |
| Qin, HJ | 1 |
| Zhang, Z | 1 |
| Xu, Y | 1 |
| Yang, XC | 1 |
| Zhao, DM | 1 |
| Li, XN | 1 |
| Sun, LK | 1 |
| Noh, H | 1 |
| Oh, EY | 1 |
| Seo, JY | 1 |
| Yu, MR | 1 |
| Kim, YO | 1 |
| Ha, H | 1 |
| Lee, HB | 1 |
5 other studies available for valproic acid and Diabetic Nephropathies
| Article | Year |
|---|---|
Valproic acid attenuates cellular senescence in diabetic kidney disease through the inhibition of complement C5a receptors.
Topics: Animals; Cellular Senescence; Complement C5a; Diabetes Mellitus, Experimental; Diabetic Nephropathie | 2022 |
Valproic acid attenuates cellular senescence in diabetic kidney disease through the inhibition of complement C5a receptors.
Topics: Animals; Cellular Senescence; Complement C5a; Diabetes Mellitus, Experimental; Diabetic Nephropathie | 2022 |
Valproic acid attenuates cellular senescence in diabetic kidney disease through the inhibition of complement C5a receptors.
Topics: Animals; Cellular Senescence; Complement C5a; Diabetes Mellitus, Experimental; Diabetic Nephropathie | 2022 |
Valproic acid attenuates cellular senescence in diabetic kidney disease through the inhibition of complement C5a receptors.
Topics: Animals; Cellular Senescence; Complement C5a; Diabetes Mellitus, Experimental; Diabetic Nephropathie | 2022 |
Valproic acid attenuates cellular senescence in diabetic kidney disease through the inhibition of complement C5a receptors.
Topics: Animals; Cellular Senescence; Complement C5a; Diabetes Mellitus, Experimental; Diabetic Nephropathie | 2022 |
Valproic acid attenuates cellular senescence in diabetic kidney disease through the inhibition of complement C5a receptors.
Topics: Animals; Cellular Senescence; Complement C5a; Diabetes Mellitus, Experimental; Diabetic Nephropathie | 2022 |
Valproic acid attenuates cellular senescence in diabetic kidney disease through the inhibition of complement C5a receptors.
Topics: Animals; Cellular Senescence; Complement C5a; Diabetes Mellitus, Experimental; Diabetic Nephropathie | 2022 |
Valproic acid attenuates cellular senescence in diabetic kidney disease through the inhibition of complement C5a receptors.
Topics: Animals; Cellular Senescence; Complement C5a; Diabetes Mellitus, Experimental; Diabetic Nephropathie | 2022 |
Valproic acid attenuates cellular senescence in diabetic kidney disease through the inhibition of complement C5a receptors.
Topics: Animals; Cellular Senescence; Complement C5a; Diabetes Mellitus, Experimental; Diabetic Nephropathie | 2022 |
Valproate attenuates the proteinuria, podocyte and renal injury by facilitating autophagy and inactivation of NF-κB/iNOS signaling in diabetic rat.
Topics: Acetylation; Animals; Apoptosis; Autophagy; Biomarkers; Diabetic Nephropathies; DNA Damage; Enzyme A | 2015 |
Sodium valproate ameliorates diabetes-induced fibrosis and renal damage by the inhibition of histone deacetylases in diabetic rat.
Topics: Acetylation; Acute Kidney Injury; Animals; Cytokines; Diabetes Mellitus, Experimental; Diabetic Neph | 2015 |
Valproate attenuates diabetic nephropathy through inhibition of endoplasmic reticulum stress‑induced apoptosis.
Topics: Acetylation; Animals; Apoptosis; Diabetic Nephropathies; Disease Models, Animal; Endoplasmic Reticul | 2016 |
Histone deacetylase-2 is a key regulator of diabetes- and transforming growth factor-beta1-induced renal injury.
Topics: Acetylcysteine; Amides; Animals; Antioxidants; Biphenyl Compounds; Cell Line; Cell Transdifferentiat | 2009 |